ALSO NOTED: Pro-compulsory license official reassigned in Thailand; Galderma to nab CollaGenex for $420M

> Thailand's FDA chief was transferred to an "inactive post" in a move observers consider linked to the government's rethinking of previous officials' policy of quashing cancer-drug patents. Report

> Dermatology drugs specialist Galderma Pharma said it has agreed to buy CollaGenex Pharmaceuticals for $16.60 per share cash, or $420 million. Report

> Barr Pharmaceuticals reached a $6 million settlement with Iowa and 33 other states that sued the company for agreeing not to launch a generic version of the Warner Chilcott contraceptive Ovcon. Report

> The U.K.'s drug advisory panel says children as young as 12 should get nicotine patches if they have a serious smoking problem. Report

> NPS Pharmaceuticals said its president and CEO Tony Coles would step down to become president and CEO of Onyx Pharmaceuticals; he will be succeeded at NPS by EVP and COO Francois Nader. Report

> More bad news on the big drought of new drug approvals. Not only are approvals at a 25-year low while non-approvable letters and black box warnings are on the rise. Now "refuse-to-file" letters are also spiking. Report

And Finally... One in 20 tuberculosis cases worldwide is now resistant to two or more drugs, and an extensively resistant form is active in 45 countries. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.